Health Technology Assessment

All Items

• Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy

  Giuseppe Pompilio, Davide Integlia

  138-145

  DOI: https://doi.org/10.33393/grhta.2022.2474

• Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain

  Prof. Dr. Jaime Rodríguez Quintosa, Dr. Cintia Cristina Ago, Dr. Antoni Sicras Mainar, Dr. Renata Villoro, Dr. Inés Pérez-Román

  133-137

  DOI: https://doi.org/10.33393/grhta.2022.2439

• Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

  Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria

  123-132

  DOI: https://doi.org/10.33393/grhta.2022.2470

• Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation

  Chiara Bini, Martina Paoletti, Andrea Marcellusi, Carlo Tomino, Francesco Saverio Mennini

  105-116

  DOI: https://doi.org/10.33393/grhta.2022.2412

• Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

  Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo

  82-90

  DOI: https://doi.org/10.33393/grhta.2022.2449

• The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

  Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi

  73-81

  DOI: https://doi.org/10.33393/grhta.2022.2415

• Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis

  Filippo Rumi, Michele Basile, Americo Cicchetti, Rosario Contiguglia, Antonella Pentassuglia, Alessandro Oliva, Gianenrico Senna, Marco Bonavia, Francesco Scarpelli, Marco Benvenuto

  58-67

  DOI: https://doi.org/10.33393/grhta.2022.2290

• Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

  Francesco Saverio Mennini, Martina Paoletti, Chiara Bini, Andrea Marcellusi, Marco Falcone, Massimo Andreoni

  45-57

  DOI: https://doi.org/10.33393/grhta.2022.2287

• Distribution methods of ostomy and incontinence aids in the Italian healthcare setting: an evaluation questionnaire and social burden of direct distribution

  Filippo Rumi, Francesca Orsini, Vincenzo Falabella, Pier Raffaele Spena, Americo Cicchetti

  36-44

  DOI: https://doi.org/10.33393/grhta.2022.2292

• Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

  Giuseppe Pompilio, Alessandro Morabito, Diego L. Cortinovis, Davide Integlia

  22-29

  DOI: https://doi.org/10.33393/grhta.2022.2351

• A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

  Néboa Zozaya, Teresa Caballero, Teresa González-Quevedo, Pedro Gamboa Setien, M. Ángeles González, Ramón Jódar, José Luis Poveda-Andrés, Encarna Guillén-Navarro, Agustín Rivero Cuadrado, Álvaro Hidalgo-Vega

  14-21

  DOI: https://doi.org/10.33393/grhta.2022.2333

• Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

  Andrea Aiello, Maria E. Mancuso, Serena Leone, Letizia Rossi, Lorenzo Cioni, Cristina Teruzzi

  9-13

  DOI: https://doi.org/10.33393/grhta.2022.2331

• Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project

  Stefania Bramanti, Matteo Carrabba, Alice Di Rocco, Elena Fabris, Luca Gastaldi, Paolo Locatelli, Maria Chiara Tisi

  1-8

  DOI: https://doi.org/10.33393/grhta.2022.2340

• Cost-utility analysis of evolocumab in patients with ASCVD in Italy

  Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Emanuela Arcangeli, Laura Martinez, Francesc Sorio Vilela, Francesco Saverio Mennini

  155-167

  DOI: https://doi.org/10.33393/grhta.2021.2255

• Evaluation of epidemiological and economic consequences due to the delay in treatment of hiv-positive patients caused by the covid-19 pandemic

  Andrea Marcellusi, Chiara Bini, Massimo Andreoni, Andrea Antinori, Francesco Saverio Mennini

  147-154

  DOI: https://doi.org/10.33393/grhta.2021.2279

• The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective

  Luis J. Pastor-Quirós, Edgar P. Correa-Díaz

  140-146

  DOI: https://doi.org/10.33393/grhta.2021.2273

• Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

  Paolo Gisondi, Francesco Loconsole, Paola Raimondo, Roberto Ravasio

  120-130

  DOI: https://doi.org/10.33393/grhta.2021.2258

• Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

  Filippo Rumi, Michele Basile, Americo Cicchetti

  105-113

  DOI: https://doi.org/10.33393/grhta.2021.2247

• Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

  Michele Basile, Lorenzo Somaini, Americo Cicchetti

  96-104

  DOI: https://doi.org/10.33393/grhta.2021.2237

• Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia

  Michele Basile, Filippo Rumi, Americo Cicchetti

  87-95

  DOI: https://doi.org/10.33393/grhta.2021.2238

• Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

  Mario Boccadoro, Patrizia Berto, Sara Bringhen, Elena Zamagni, Patrizia Tosi, Nicola Cascavilla, Nicola Giuliani, Donato Mannina, Renato Zambello, Francesca Patriarca, Vittorio Montefusco, Mariella Grasso, Francesco Di Raimondo, Massimo Offidani, Maria Teresa Petrucci, Pellegrino Musto

  80-86

  DOI: https://doi.org/10.33393/grhta.2021.2245

• Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

  Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi

  69-79

  DOI: https://doi.org/10.33393/grhta.2021.2267

• Author’s reply to comments on “Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain”

  Néboa Zozaya

  68

  DOI: https://doi.org/10.33393/grhta.2021.2272

• Comments on "Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain"

  David Gomez

  67

  DOI: https://doi.org/10.33393/grhta.2021.2261

• Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

  Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi

  53-57

  DOI: https://doi.org/10.33393/grhta.2021.2222